Sabby Management, LLC

recently revealed that they own 10% of Geovax Labs Inc (OTCMKTS:GOVX) in a Form 13G/A disclosure that was filed with the SEC on Thursday, January 4th. The investor owns 8,307,476 shares of the stock worth $490,141. The reporting parties listed on the disclosure included Sabby Healthcare Master Fund, Ltd, Sabby Volatility Warrant Master Fund, Ltd, Sabby Management, LLC and Hal Mintz. The filing is available through Edgar at this hyperlink.

Separately, ValuEngine raised Geovax Labs from a “strong sell” rating to a “sell” rating in a research report on Friday, November 10th.

Geovax Labs Inc (GOVX) remained flat at $$0.06 on Thursday. 288,487 shares of the company traded hands, compared to its average volume of 719,583. The company has a market capitalization of $4.87, a price-to-earnings ratio of -1.18 and a beta of 0.11. Geovax Labs Inc has a 1-year low of $0.02 and a 1-year high of $0.10.

Geovax Labs (OTCMKTS:GOVX) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.01). The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.30 million. research analysts predict that Geovax Labs Inc will post -0.04 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/sabby-management-llc-maintains-stake-in-geovax-labs-inc-govx/1794481.html.

Geovax Labs Profile

GeoVax Labs, Inc (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.

Want to see what other hedge funds are holding GOVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geovax Labs Inc (OTCMKTS:GOVX).

Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with Analyst Ratings Network's FREE daily email newsletter.